サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：高脂血症の世界市場（2022年～2028年）：タイプ別、治療法別、流通チャネル別、地域別の市場規模調査と予測
市場調査レポート
商品コード
1084067

高脂血症の世界市場（2022年～2028年）：タイプ別、治療法別、流通チャネル別、地域別の市場規模調査と予測

Global Hyperlipidemia Market Size study, By Type, By Treatment, By Distribution Channel, and Regional Forecasts 2022-2028
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
高脂血症の世界市場（2022年～2028年）：タイプ別、治療法別、流通チャネル別、地域別の市場規模調査と予測
出版日: 2022年05月27日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の高脂血症の市場規模は、2022年～2028年の予測期間中に健全な成長率で成長すると予想されています。市場を牽引する主な要因には、高脂血症の有病率の上昇、医療インフラへの投資の増加、老年人口の増加などがあります。しかし、治療にかかる費用の高さや熟練した専門家の不足が、予測期間における市場の成長を阻害しています。また、研究開発活動の増加や医薬品の承認・上市の増加は、予測期間中の市場需要の触媒として作用すると予測されます。

当レポートでは世界の高脂血症市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の高脂血症市場：定義と範囲

第3章 世界の高脂血症：市場力学

  • 高脂血症市場：影響分析（2020年～2028年）

第4章 世界の高脂血症市場：業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要な投資機会
  • 主要な成功戦略

第5章 リスク評価：COVID-19の影響

    • 業界に対するCOVID-19の全体的な影響の評価
    • COVID-19以前およびCOVID-19後の市場シナリオ

第6章 世界の高脂血症市場：タイプ別

  • 市場のスナップショット
  • 実績：潜在的な分析
  • 市場規模の推計と予測（2018年～2028年）
  • サブセグメント分析
    • 家族性
    • 後天性

第7章 世界の高脂血症市場：治療法別

  • 市場のスナップショット
  • 実績：潜在的な分析
  • 市場規模の推計と予測（2018年～2028年）
  • サブセグメント分析
    • スタチン
    • 胆汁酸封鎖剤
    • コレステロール吸収阻害剤
    • フィブリン酸誘導体
    • 組み合わせ
    • その他

第8章 世界の高脂血症市場：流通チャネル別

  • 市場のスナップショット
  • 実績：潜在的な分析
  • 市場規模の推計と予測（2018年～2028年）
  • サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他

第9章 世界の高脂血症市場：地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第10章 競合情勢

  • 主な市場戦略
  • 企業プロファイル
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Johnson & Johnson Private Limited
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.

第11章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Hyperlipidemia Market, report scope
  • TABLE 2. Global Hyperlipidemia Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global Hyperlipidemia Market estimates & forecasts by Type 2018-2028 (USD Million)
  • TABLE 4. Global Hyperlipidemia Market estimates & forecasts by Treatment 2018-2028 (USD Million)
  • TABLE 5. Global Hyperlipidemia Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 6. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 7. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 8. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. U.S. Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 17. U.S. Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 18. U.S. Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 19. Canada Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 20. Canada Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. Canada Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 22. UK Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 23. UK Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. UK Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 25. Germany Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 26. Germany Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. Germany Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 28. RoE Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 29. RoE Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. RoE Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 31. China Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 32. China Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. China Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 34. India Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 35. India Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. India Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 37. Japan Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 38. Japan Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. Japan Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 40. RoAPAC Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 41. RoAPAC Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. RoAPAC Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 43. Brazil Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 44. Brazil Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Brazil Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 46. Mexico Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 47. Mexico Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. Mexico Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 49. RoLA Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 50. RoLA Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. RoLA Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 52. Row Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 53. Row Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. Row Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 55. List of secondary sources, used in the study of global Hyperlipidemia Market
  • TABLE 56. List of primary sources, used in the study of global Hyperlipidemia Market
  • TABLE 57. Years considered for the study
  • TABLE 58. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Hyperlipidemia Market, research methodology
  • FIG 2. Global Hyperlipidemia Market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Hyperlipidemia Market, key trends 2021
  • FIG 5. Global Hyperlipidemia Market, growth prospects 2022-2028
  • FIG 6. Global Hyperlipidemia Market, porters 5 force model
  • FIG 7. Global Hyperlipidemia Market, pest analysis
  • FIG 8. Global Hyperlipidemia Market, value chain analysis
  • FIG 9. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global Hyperlipidemia Market, regional snapshot 2018 & 2028
  • FIG 15. North America Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 16. Europe Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 17. Asia Pacific Hyperlipidemia market 2018 & 2028 (USD Million)
  • FIG 18. Latin America Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 19. Global Hyperlipidemia Market, company market share analysis (2021)
目次

Global Hyperlipidemia Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Hyperlipidemia is also known as high cholesterol or dyslipidemia. It is a condition there are high levels of fat particles (lipids) present in the blood. The rising prevalence of hyperlipidemia, increasing investment in healthcare infrastructure, and growing number of geriatric populations are the primary factors fostering the market demand across the globe. For instance, as per the World Health Organization (WHO), the global population aged 60 years and above is expected to rise from 605 million in 2000 to 2 billion by the year 2050. Consequentially, the increasing aged population is more prone to get affected by a variety of diseases, which is surging the market demand across the globe. However, the high cost associated with the treatment and shortage of skilled professionals impede the growth of the market over the forecast period of 2022-2028. Also, an increase in the number of research and development activities and rising drug approvals and launches are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Hyperlipidemia Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing incidences of hyperlipidemia, along with rising technological developments. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing expenditure on healthcare facilities, as well as the increasing geriatric population, would create lucrative growth prospects for the Hyperlipidemia Market across the Asia-Pacific region.

Major market players included in this report are:

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Johnson & Johnson Private Limited

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Regeneron Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Familial

Acquired

By Treatment:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

Combination

Others

By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Hyperlipidemia Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Hyperlipidemia Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Hyperlipidemia Market, by Type, 2020-2028 (USD Million)
    • 1.2.3. Hyperlipidemia Market, by Treatment, 2020-2028 (USD Million)
    • 1.2.4. Hyperlipidemia Market, by Distribution Channel, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hyperlipidemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hyperlipidemia Market Dynamics

  • 3.1. Hyperlipidemia Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of hyperlipidemia
      • 3.1.1.2. Growing number of geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost associated with the treatment
      • 3.1.2.2. Dearth of skilled professionals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the number of research and development activities
      • 3.1.3.2. Rising drug approvals and launches

Chapter 4. Global Hyperlipidemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 market scenario

Chapter 6. Global Hyperlipidemia Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Hyperlipidemia Market by Type, Performance - Potential Analysis
  • 6.3. Global Hyperlipidemia Market Estimates & Forecasts by Type, 2018-2028 (USD Million)
  • 6.4. Hyperlipidemia Market, Sub Segment Analysis
    • 6.4.1. Familial
    • 6.4.2. Acquired

Chapter 7. Global Hyperlipidemia Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Hyperlipidemia Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Hyperlipidemia Market Estimates & Forecasts by Treatment, 2018-2028 (USD Million)
  • 7.4. Hyperlipidemia Market, Sub Segment Analysis
    • 7.4.1. Statins
    • 7.4.2. Bile Acid Sequestrants
    • 7.4.3. Cholesterol Absorption Inhibitors
    • 7.4.4. Fibric Acid Derivatives
    • 7.4.5. Combination
    • 7.4.6. Others

Chapter 8. Global Hyperlipidemia Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Hyperlipidemia Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Hyperlipidemia Market Estimates & Forecasts by Distribution Channel, 2018-2028 (USD Million)
  • 8.4. Hyperlipidemia Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
    • 8.4.4. Others

Chapter 9. Global Hyperlipidemia Market, Regional Analysis

  • 9.1. Hyperlipidemia Market, Regional Market Snapshot
  • 9.2. North America Hyperlipidemia Market
    • 9.2.1. U.S. Hyperlipidemia Market
      • 9.2.1.1. Type breakdown estimates & forecasts, 2018-2028
      • 9.2.1.2. Treatment breakdown estimates & forecasts, 2018-2028
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2018-2028
    • 9.2.2. Canada Hyperlipidemia Market
  • 9.3. Europe Hyperlipidemia Market Snapshot
    • 9.3.1. U.K. Hyperlipidemia Market
    • 9.3.2. Germany Hyperlipidemia Market
    • 9.3.3. France Hyperlipidemia Market
    • 9.3.4. Spain Hyperlipidemia Market
    • 9.3.5. Italy Hyperlipidemia Market
    • 9.3.6. Rest of Europe Hyperlipidemia Market
  • 9.4. Asia-Pacific Hyperlipidemia Market Snapshot
    • 9.4.1. China Hyperlipidemia Market
    • 9.4.2. India Hyperlipidemia Market
    • 9.4.3. Japan Hyperlipidemia Market
    • 9.4.4. Australia Hyperlipidemia Market
    • 9.4.5. South Korea Hyperlipidemia Market
    • 9.4.6. Rest of Asia Pacific Hyperlipidemia Market
  • 9.5. Latin America Hyperlipidemia Market Snapshot
    • 9.5.1. Brazil Hyperlipidemia Market
    • 9.5.2. Mexico Hyperlipidemia Market
  • 9.6. Rest of The World Hyperlipidemia Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Pfizer Inc.
    • 10.2.3. GlaxoSmithKline plc
    • 10.2.4. Novartis AG
    • 10.2.5. Johnson & Johnson Private Limited
    • 10.2.6. Sun Pharmaceutical Industries Ltd.
    • 10.2.7. Merck & Co., Inc.
    • 10.2.8. Bristol-Myers Squibb Company
    • 10.2.9. Eli Lilly and Company
    • 10.2.10. Regeneron Pharmaceuticals Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption